![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Dendritic cell immunotherapy is emerging as a promising addition to the multimodal treatment of patients with glioblastoma multiform. Initial Phase I and II trials have demonstrated favorable outcomes with minimal toxicity. In this editorial, the current status and the future challenges of this therapy are discussed.
Financial & competing interests disclosure
S Polyzoidis is subinvestigator in the Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM). K Ashkan is chief investigator for Europe in the Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.